PE20201068A1 - Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos - Google Patents

Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos

Info

Publication number
PE20201068A1
PE20201068A1 PE2020001510A PE2020001510A PE20201068A1 PE 20201068 A1 PE20201068 A1 PE 20201068A1 PE 2020001510 A PE2020001510 A PE 2020001510A PE 2020001510 A PE2020001510 A PE 2020001510A PE 20201068 A1 PE20201068 A1 PE 20201068A1
Authority
PE
Peru
Prior art keywords
heteroaryl
halogen
same
pharmaceutical use
compounds substituted
Prior art date
Application number
PE2020001510A
Other languages
English (en)
Inventor
Tomoya Miura
Shintaro Hirashima
Tomoyuki Manabe
Tetsuya Iida
Kentaro Sakurai
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of PE20201068A1 publication Critical patent/PE20201068A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Abstract

La presente invencion se refiere a un compuesto derivado de pirazol sustituido con heteroarilo de formula [X] o una sal farmaceuticamente aceptable del mismo, en donde: R1 es hidrogeno o halogeno; R2 es alquilo C1-C6 o haloalquilo C1-C6; el anillo het es: (1) piridilo sustituido con R3, o (2) pirazinilo, pirimidinilo, o piridazinilo sustituido opcionalmente con R4; R3 es ciano, halogeno o haloalquilo C1-C3; R4 es halogeno, hidroxi, entre otros. Tambien se refiere a una composicion que lo comprende. Dicho compuesto es un inhibidor del cotransportador de sodio-glucosa 1 (SGTL1), siendo util en el tratamiento de la diabetes, en especial, la diabetes de tipo 2.
PE2020001510A 2018-04-04 2019-04-03 Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos PE20201068A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018072557 2018-04-04
PCT/JP2019/014721 WO2019194207A1 (ja) 2018-04-04 2019-04-03 ヘテロアリールで置換されたピラゾール化合物及びその医薬用途

Publications (1)

Publication Number Publication Date
PE20201068A1 true PE20201068A1 (es) 2020-10-19

Family

ID=68100257

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001510A PE20201068A1 (es) 2018-04-04 2019-04-03 Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos

Country Status (19)

Country Link
US (2) US10988462B2 (es)
EP (1) EP3778593A4 (es)
JP (3) JP7130588B2 (es)
KR (1) KR20200139696A (es)
CN (1) CN111902408B (es)
AR (1) AR114465A1 (es)
AU (1) AU2019249560B2 (es)
BR (1) BR112020019939A2 (es)
CA (1) CA3089092A1 (es)
CL (1) CL2020002550A1 (es)
CO (1) CO2020012353A2 (es)
IL (1) IL277686A (es)
MX (1) MX2020010433A (es)
PE (1) PE20201068A1 (es)
PH (1) PH12020551624A1 (es)
SG (1) SG11202009179TA (es)
TW (1) TWI805727B (es)
WO (1) WO2019194207A1 (es)
ZA (1) ZA202006053B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI805699B (zh) 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
AU2020343585A1 (en) * 2019-09-04 2022-03-10 Japan Tobacco Inc. Chronic kidney disease treatment or prevention method
EP4026564A4 (en) * 2019-09-04 2023-03-15 Japan Tobacco Inc. THERAPEUTIC OR PROPHYLACTIC PROCEDURE FOR DIABETES USING COMBINATION MEDICATION
KR20220156574A (ko) 2020-03-19 2022-11-25 니뽄 다바코 산교 가부시키가이샤 만성 심부전의 치료 또는 예방 방법

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2665898B1 (fr) 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
JPH04247081A (ja) 1991-02-01 1992-09-03 Takeda Chem Ind Ltd ５員複素環酸アミド類
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
PL377848A1 (pl) 2003-02-07 2006-02-20 Daiichi Pharmaceutical Co., Ltd. Pochodne pirazoli
AU2004200420A1 (en) 2003-03-11 2004-09-30 Astellas Pharma Inc. Inhibitor of cyclooxygenase
JP2006182648A (ja) 2003-04-08 2006-07-13 Dai Ichi Seiyaku Co Ltd ７員複素環誘導体
WO2004110351A2 (en) 2003-05-14 2004-12-23 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis c virus
EP1637539B1 (en) * 2003-06-20 2012-01-18 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, drug composition containing the same and production intermediate therefor
TW200526588A (en) 2003-11-17 2005-08-16 Smithkline Beecham Corp Chemical compounds
TW200526641A (en) 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
DE102004028241B4 (de) 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
CA2572745A1 (en) 2004-07-07 2006-02-16 Teresa Beeson Pyrazole amide derivatives, compositions containing such compounds and methods of use
US9168278B2 (en) 2004-11-16 2015-10-27 Gw Pharma Limited Use for cannabinoid
CA2590533C (en) * 2004-11-23 2010-09-07 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia
JP2008007405A (ja) 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
JP4137956B2 (ja) 2005-06-08 2008-08-20 日本たばこ産業株式会社 複素環化合物
WO2006132436A1 (ja) 2005-06-08 2006-12-14 Japan Tobacco Inc. 複素環化合物
WO2007034279A2 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
TWI378922B (en) * 2005-10-21 2012-12-11 Mitsubishi Tanabe Pharma Corp A pyrazole compound
WO2007098826A2 (en) 2006-01-18 2007-09-07 Siena Biotech S.P.A. Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
US20080027014A1 (en) * 2006-07-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Novel SGLT inhibitors
EP2079728B1 (en) 2006-10-10 2013-09-25 Amgen Inc. N-aryl pyrazole compounds for use against diabetes
WO2008061796A2 (en) 2006-11-24 2008-05-29 Ac Immune Sa Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
JP5292300B2 (ja) 2006-11-24 2013-09-18 エーシー イミューン ソシエテ アノニム 例えばアルツハイマー病のようなアミロイドまたはアミロイド様タンパク質に関連する疾患の治療のためのｎ−（メチル）−１ｈ−ピラゾール−３−アミン誘導体、ｎ−（メチル）−ピリジン−２−アミン誘導体、およびｎ−（メチル）−トリゾール−２−アミン誘導体
CL2008000119A1 (es) 2007-01-16 2008-05-16 Wyeth Corp Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
JP4994295B2 (ja) 2007-04-20 2012-08-08 田辺三菱製薬株式会社 医薬組成物
US20090181952A1 (en) 2008-01-14 2009-07-16 Wyeth Compounds useful as alpha7 nicotinic acetylcholine receptor agonists
US8703761B2 (en) 2008-07-15 2014-04-22 Novartis Ag Organic compounds
JP6155187B2 (ja) 2010-03-30 2017-06-28 ヴァーセオン コーポレイション トロンビンの阻害剤としての多置換芳香族化合物
WO2011161615A1 (en) 2010-06-24 2011-12-29 Ranbaxy Laboratories Limited 5-lipoxygenase inhibitors
AR087701A1 (es) 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
UA113086C2 (xx) 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1
CN111303159A (zh) * 2014-10-02 2020-06-19 豪夫迈·罗氏有限公司 用于治疗由布鲁顿酪氨酸激酶(btk)介导的疾病的吡唑甲酰胺化合物
TWI805699B (zh) 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途

Also Published As

Publication number Publication date
JP2019182852A (ja) 2019-10-24
AU2019249560B2 (en) 2023-10-05
CN111902408B (zh) 2023-11-14
EP3778593A4 (en) 2021-12-22
MX2020010433A (es) 2020-10-28
JP2024050645A (ja) 2024-04-10
CA3089092A1 (en) 2019-10-10
JP2022166280A (ja) 2022-11-01
CN111902408A (zh) 2020-11-06
US10988462B2 (en) 2021-04-27
ZA202006053B (en) 2022-03-30
CL2020002550A1 (es) 2021-01-15
AR114465A1 (es) 2020-09-09
US20190330193A1 (en) 2019-10-31
WO2019194207A1 (ja) 2019-10-10
IL277686A (en) 2020-11-30
BR112020019939A2 (pt) 2021-01-05
CO2020012353A2 (es) 2021-01-18
SG11202009179TA (en) 2020-10-29
TW201942114A (zh) 2019-11-01
JP7130588B2 (ja) 2022-09-05
RU2020132318A (ru) 2022-04-29
KR20200139696A (ko) 2020-12-14
TWI805727B (zh) 2023-06-21
PH12020551624A1 (en) 2021-07-12
US20220048896A1 (en) 2022-02-17
AU2019249560A1 (en) 2020-07-23
EP3778593A1 (en) 2021-02-17
RU2020132318A3 (es) 2022-04-29

Similar Documents

Publication Publication Date Title
PE20201068A1 (es) Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos
PE20220931A1 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
PE20181094A1 (es) Derivados heterociclicos condensados sustituidos por 2-(het)arilo como pesticidas
PE20181093A1 (es) Compuestos heterociclicos y usos de los mismos
AR066882A1 (es) Derivados de oxadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de trastornos asociados con la disfuncion del glutamato.
AR074238A1 (es) Compuesto de n-{[(1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4,1.0]hept-4-il]metil}-2-heteroarilamina, su uso para la preparacion de un medicamento util para el tratamiento de una enfermedad que requiere un antagonista del receptor de orexina humano y composicion farmaceutica que lo comprende
UY30897A1 (es) Derivados de pentafluorotiobenzamidoacetonitrilo, composiciones conteniéndolos y aplicaciones
AR070636A1 (es) Derivados de piridina, composicion farmaceutica y uso terapeutico
AR047890A1 (es) Derivados de azabiciclo[3.1.0]hexano como moduladores de los receptores de dopamina d3
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
UY30499A1 (es) Derivados de amina utiles como agentes anticancerigenos
CL2012000999A1 (es) Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina.
CR20160548A (es) Nuevos Derivados de Pirazolo Pirimidina y su Uso como Inhibidores de MALT1
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
AR057855A1 (es) Derivados de pirazina y composicion farmaceutica
CO6241157A2 (es) "derivados de 6-(pirrolidin-3-il)-1h-pirazolo{3,4-d}pirimidin-4(5h)-ona utiles como inhibidores de pde9"
AR061815A1 (es) Compuesto de oxo-prolinamida composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento
CR9267A (es) Derivados de quinazolina para el tratamiento de la tuberculosis latente
CL2008001669A1 (es) Compuestos derivados de piperidina/piperazina inhibidora de dgat-1; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento de la obesidad, dislipidemia, fibrosis hepatica y diabetes tipo ii, entre otras.
GB201201744D0 (en) Novel compounds
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
PE20141691A1 (es) Compuestos con actividad nematicida
ES2567311T3 (es) 6-(3-Aza-biciclo[3.1.0]hex-3-il)-2-fenil-pirimidinas como antagonistas del receptor de ADP
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
AR046996A1 (es) Derivados de amino-pirimidinas